Adlai Nortye (ANL) Total Non-Current Liabilities (2022 - 2025)
Adlai Nortye (ANL) reported Total Non-Current Liabilities of $1.1 million for Q4 2025, up 165.18% year-over-year from $425000.0 in Q4 2024, and up 338.52% on a QoQ basis from $257000.0 in Q2 2025.
Adlai Nortye (ANL) has 4 years of Total Non-Current Liabilities data on file, last reported at $1.1 million in Q4 2025.
- Quarterly Total Non-Current Liabilities rose 165.18% year-over-year to $1.1 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $1.1 million (up 165.18% YoY) and the FY2025 annual result came in at $1.1 million, up 165.18% from the prior year.
- Total Non-Current Liabilities advanced to $1.1 million in Q4 2025 per ANL's latest filing, from $257000.0 in the prior quarter.
- Across five years, Total Non-Current Liabilities topped out at $5.5 million in Q4 2023 and bottomed at $257000.0 in Q2 2025.
- The 4-year median for Total Non-Current Liabilities is $1.1 million (2025), against an average of $1.7 million.
- The widest annual swing landed in 2023, when Total Non-Current Liabilities soared 342.48%; it then tumbled 92.23% in 2024.
- Tracing ANL's Total Non-Current Liabilities over 4 years: stood at $1.2 million in 2022, then soared by 342.48% to $5.5 million in 2023, then plunged by 92.23% to $425000.0 in 2024, then surged by 165.18% to $1.1 million in 2025.
- Per Business Quant, the three latest ANL Total Non-Current Liabilities figures stand at $1.1 million (Q4 2025), $257000.0 (Q2 2025), and $425000.0 (Q4 2024).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,638,563.89 Bn | 1,638,563.89 Bn | - | 11.03 Mn |
| 2 | Alterity Therapeutics | 767,934.24 Bn | 767,934.20 Bn | - | 42,980.09 |
| 3 | Legend Biotech | 2,937.00 Bn | 2,936.10 Bn | 242.10 Mn | 95.20 Mn |
| 4 | Nanobiotix | 2,282.79 Bn | 2,282.72 Bn | - | 110.28 Mn |
| 5 | Akari Therapeutics | 2,169.69 Bn | 2,169.69 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 110.41 Bn | 103.16 Bn | 2.59 Bn | 5.87 Bn |
| 7 | Regeneron Pharmaceuticals | 66.44 Bn | 57.69 Bn | 3.31 Bn | 7.32 Bn |
| 8 | Evaxion A | 65.44 Bn | 65.42 Bn | - | - |
| 9 | Alnylam Pharmaceuticals | 39.53 Bn | 36.52 Bn | 959.66 Mn | 4.05 Bn |
| 10 | Adlai Nortye | 23,840.00 | -8.03 Mn | - | 1.13 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 1.13 Mn |
| Jun 30, 2025 | 257,000.00 |
| Dec 31, 2024 | 425,000.00 |
| Dec 31, 2023 | 5.47 Mn |
| Dec 31, 2022 | 1.24 Mn |